

Henry Schein Reports Record Fourth Quarter and Full Year Results

February 21, 2007

Fourth Quarter Diluted EPS from Continuing Operations Increases 25% to \$0.70

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 21, 2007--Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported financial results for the quarter and year ended December 30, 2006.

Net sales for the fourth quarter of 2006 were \$1.5 billion, an increase of 11.6% from the fourth quarter of 2005. This increase includes 9.3% local currency growth (2.3% internally generated and 7.0% from acquisitions net of divestiture) and 2.3% related to foreign currency exchange. The fourth quarter of 2006 included one less week compared with the fourth quarter of 2005, which was part of a 53-week fiscal year. The Company estimates that the reported 2.3% internal sales growth in local currencies was therefore, approximately 7.3% adjusting for the extra week in the 2005 fourth quarter (See Exhibit A for details of sales growth).

Net income and income from continuing operations for the fourth quarter of 2006 were \$63.0 million or \$0.70 per diluted share. There was no impact of discontinued operations for the current quarter. Fourth quarter 2006 income and diluted earnings per share from continuing operations were up 27.4% and 25.0%, respectively, compared with the prior-year fourth quarter.

Effective January 1, 2006, the Company adopted the new accounting rules on expensing stock-based compensation per Financial Accounting Standards (FAS) No. 123R on a retrospective basis. All periods presented have been adjusted to give effect to FAS No. 123R, which amounted to approximately \$0.04 per share in the fourth quarter of 2006 and \$0.03 per share in the fourth quarter of 2005.

"Our fourth quarter results featured double-digit sales growth in each of our business groups, when adjusting for the extra week in the 2005 fourth quarter, with particular strength in dental equipment," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "As we close out a milestone year with more than \$5 billion in net sales, we enter 2007 enthusiastic about our markets, our business model and the future of Henry Schein."

For the fourth quarter, Dental sales increased 12.9%, including 12.5% growth in local currencies (6.0% internally generated and 6.5% from acquisitions) and 0.4% related to foreign currency exchange. The Company estimates that the reported 6.0% Dental internal sales growth in local currencies was 11.5% adjusting for the extra week in the 2005 fourth quarter, including Dental consumable merchandise growth of 5.6% and Dental equipment sales and service growth of 26.6%.

"Continued market-share gains in our Dental Group were lead by equipment sales and service growth, which reflects robust demand for high-tech products including our new exclusive relationships with Biolase Technology, Inc. and Imaging Sciences International, Inc.," commented Mr. Bergman.

Medical sales increased 6.1% during the fourth quarter (3.5% decline in internal sales growth offset by 9.6% acquisition growth net of divestiture). The Company estimates that total Medical sales growth of 6.1% as reported was 11.1% adjusting for the extra week in the 2005 fourth quarter. The Company also estimates that the reported Medical Group internal sales decline of 3.5% equated to 1.5% internal sales growth adjusting for the extra week. "Excluding pharmaceutical sales, the internal growth rate for our Medical Group, adjusting for the extra week, was approximately equal to our estimate for market growth," added Mr. Bergman.

For the quarter, International sales increased 15.9%, including 7.7% growth in local currencies (3.3% internally generated and 4.4% from acquisitions), and 8.2% related to foreign currency exchange. The Company estimates that reported International internal sales growth in local currencies of 3.3% was 7.3% when adjusting for the extra week in the 2005 fourth quarter. "Sales growth was particularly strong in Germany and Spain," commented Mr. Bergman.

Technology and Value-Added Services sales during the fourth quarter of 2006 were 15.6% ahead of prior year, including 15.4% growth in local currencies (9.2% internally generated and 6.2% acquisition growth) and 0.2% related to foreign currency exchange. The Company estimates that reported Technology and Value-Added Services internal sales growth of 9.2% was 17.7% when adjusting for the extra week in the 2005 fourth quarter. "Our Technology and Value-Added Services sales growth for the quarter was fueled by strong growth in software revenues," added Mr. Bergman.

Full Year Results

For 2006, net sales of \$5.15 billion represent an increase of 11.2% compared with 2005. This increase includes 10.6% local currency growth (5.2% internally generated and 5.4% from acquisitions net of divestiture) and 0.6% related to foreign currency exchange. The Company estimates that the reported 5.2% internal sales growth in local currencies was approximately 6.7% adjusting for the extra week in 2005. Income from continuing operations for 2006 was \$183.1 million reflecting 21.3% growth compared with the prior year. Earnings per diluted share from continuing operations of \$2.04 for 2006 represents 19.3% growth over 2005.

Stock Repurchase Plan

Henry Schein announced that it repurchased 295,137 shares of common stock during the fourth quarter of 2006 at an average price of \$49.34 per share. Approximately \$71 million remains authorized for future common stock repurchases. The impact of the repurchase of shares under this program on fourth quarter diluted EPS was immaterial.

2007 EPS Guidance

Henry Schein affirms 2007 financial guidance, as follows:

- 2007 diluted EPS is expected to be \$2.51 to \$2.57. This represents an increase of 23% to 26% compared with 2006 diluted EPS from continuing operations.
- This 2007 diluted EPS guidance includes Henry Schein's expectations that it will distribute approximately 20 million doses of influenza vaccine during the year.
- 2007 diluted EPS guidance is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

Fourth Quarter Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 500,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 70,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices, including DENTRIX(R) and Easy Dental(R) for dental practices, MicroMd(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs more than 11,000 people and has operations in 19 countries. The Company's sales reached a record \$5.15 billion in 2006. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect us; financial risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; financial risks associated with acquisitions; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)

	Three Months Ended		Years Ended	
	December 30, 2006	December 31, 2005	December 30, 2006	December 31, 2005
Net sales	\$1,498,936	\$1,343,141	\$5,153,097	\$4,635,929
Cost of sales	1,076,949	965,666	3,673,042	3,318,993
Gross profit	421,987	377,475	1,480,055	1,316,936
Operating expenses:				
Selling, general				

and administrative	317,431	293,036	1,175,158	1,053,798
-----	-----	-----	-----	-----
Operating income	104,556	84,439	304,897	263,138
Other income (expense):				
Interest income	4,412	2,846	16,440	7,315
Interest expense	(6,563)	(7,222)	(27,800)	(25,508)
Other, net	(115)	744	2,065	1,659
-----	-----	-----	-----	-----
Income from continuing operations before taxes, minority interest and equity in earnings of affiliates	102,290	80,807	295,602	246,604
Income taxes	(35,904)	(29,477)	(105,220)	(90,456)
Minority interest in net income of subsidiaries	(3,643)	(2,208)	(8,090)	(5,963)
Equity in earnings of affiliates	254	313	835	827
-----	-----	-----	-----	-----
Income from continuing operations	62,997	49,435	183,127	151,012
Discontinued operations:				
Loss from operations of discontinued components	-	(1,350)	(32,279)	(18,749)
Income tax benefit	-	543	12,911	7,496
-----	-----	-----	-----	-----
Loss from discontinued operations	-	(807)	(19,368)	(11,253)
-----	-----	-----	-----	-----
Net income	\$ 62,997	\$ 48,628	\$ 163,759	\$ 139,759
=====	=====	=====	=====	=====
Earnings from continuing operations per share:				
Basic	\$ 0.71	\$ 0.57	\$ 2.08	\$ 1.74
-----	-----	-----	-----	-----
Diluted	\$ 0.70	\$ 0.56	\$ 2.04	\$ 1.71
-----	-----	-----	-----	-----
Loss from discontinued operations per share:				
Basic	\$ -	\$ (0.01)	\$ (0.22)	\$ (0.13)
-----	-----	-----	-----	-----
Diluted	\$ -	\$ (0.01)	\$ (0.22)	\$ (0.13)
-----	-----	-----	-----	-----
Earnings per share:				
Basic	\$ 0.71	\$ 0.56	\$ 1.86	\$ 1.61
-----	-----	-----	-----	-----
Diluted	\$ 0.70	\$ 0.55	\$ 1.82	\$ 1.58
-----	-----	-----	-----	-----
Weighted-average common shares outstanding:				
Basic	88,580	87,075	87,952	87,006

Diluted	90,488	88,376	89,820	88,489
---------	--------	--------	--------	--------

Note: The above prior period amounts have been restated to reflect the effects of expensing stock-based compensation pursuant to our adoption of FAS 123R using the modified retrospective application.

HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

	December 30, 2006	December 31, 2005
	-----	-----
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 248,647	\$ 210,683
Available-for-sale securities	47,999	124,010
Accounts receivable, net of reserves of \$40,536 and \$52,308	610,020	582,617
Inventories, net	584,103	505,542
Deferred income taxes	28,240	35,505
Prepaid expenses and other	125,839	126,052
	-----	-----
Total current assets	1,644,848	1,584,409
Property and equipment, net	225,038	190,746
Goodwill	773,801	626,869
Other intangibles, net	161,542	123,204
Investments and other	75,917	57,892
	-----	-----
Total assets	\$2,881,146	\$2,583,120
	=====	=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 414,062	\$ 371,392
Bank credit lines	2,528	2,093
Current maturities of long-term debt	41,036	33,013
Accrued expenses:		
Payroll and related	110,401	96,113
Taxes	59,007	65,070
Other	183,054	156,433
	-----	-----
Total current liabilities	810,088	724,114
Long-term debt	455,806	489,520
Deferred income taxes	62,334	54,432
Other liabilities	60,209	53,547
Minority interest	21,746	12,353
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding	-	-
Common stock, \$.01 par value, 240,000,000 shares authorized, 88,499,321 outstanding on December 30, 2006 and 87,092,238 outstanding on December 31, 2005	885	871
Additional paid-in capital	614,551	559,266
Retained earnings	808,164	667,958
Accumulated other comprehensive income	47,363	21,059
	-----	-----
Total stockholders' equity	1,470,963	1,249,154

Total liabilities and stockholders' equity	\$2,881,146	\$2,583,120	
	=====	=====	

Note: Certain prior period amounts have been restated to reflect the effects of our adoption of FAS 123R using the modified retrospective application and a reclassification of variable rate demand notes from 'cash and cash equivalents' to 'available-for-sale securities'. Also, included in the prior period amounts are approximately \$44 million of accounts receivable, net of reserves and approximately \$16 million of inventories, net of reserves, related to discontinued operations which were sold on April 1, 2006.

HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	Three Months Ended		Years Ended	
	December 30, 2006	December 31, 2005	December 30, 2006	December 31, 2005
Cash flows from operating activities:				
Net income	\$ 62,997	\$ 48,628	\$ 163,759	\$ 139,759
Adjustments to reconcile net income to net cash provided by operating activities:				
Loss on sale of discontinued operation, net of tax	-	-	19,363	-
Depreciation and amortization	18,039	17,798	64,930	60,345
Impairment of long-lived asset	-	-	-	11,928
Stock-based compensation expense	5,531	4,885	19,464	18,249
Provision for losses on trade and other accounts receivable	529	889	2,872	6,524
Deferred income taxes	3,959	(206)	1,297	(3,869)
Stock issued to 401(k) plan	-	-	3,565	3,223
Undistributed earnings of affiliates	(254)	(313)	(835)	(827)
Minority interest in net income of subsidiaries	3,643	2,208	8,090	5,963
Other	483	(1,290)	(2,066)	(224)
Changes in operating assets and liabilities, net of acquisitions:				
Accounts receivable	(287)	27,643	(9,705)	(14,002)
Inventories	(5,991)	(27,641)	(41,958)	6,484
Other current assets	11,048	(14,336)	18,424	19,782
Accounts				

payable and accrued expenses	70,994	90,463	(11,883)	1,441
Net cash provided by operating activities	170,691	148,728	235,317	254,776
Cash flows from investing activities:				
Purchases of fixed assets	(17,073)	(14,625)	(67,000)	(50,829)
Payments for business acquisitions, net of cash acquired	(13,748)	(9,665)	(199,880)	(68,213)
Cash received from business divestiture	-	-	36,527	-
Purchases of available-for- sale securities	(57,999)	(136,700)	(222,036)	(161,445)
Proceeds from sales of available-for- sale securities	8,000	37,434	294,767	37,434
Proceeds from maturities of available-for- sale securities	2,000	-	3,280	-
Proceeds from settlement of note receivable	-	2,616	-	14,395
Net proceeds from (payments for) foreign exchange forward contract settlements	(5,633)	7,188	(22,528)	30,818
Other	3,113	(9,414)	(3,491)	(8,841)
Net cash used in investing activities	(81,340)	(123,166)	(180,361)	(206,681)
Cash flows from financing activities:				
Proceeds from (repayments of) bank borrowings	(113)	(637)	184	(3,525)
Proceeds from issuance of long-term debt	1,201	-	1,201	-
Principal payments for long-term debt	(3,860)	(3,005)	(34,537)	(8,483)
Payments for debt issuance costs	-	-	-	(650)
Proceeds from issuance of stock upon exercise of stock options	2,722	4,222	35,622	29,500

Payments for repurchases of common stock	(14,563)	(25,159)	(40,263)	(52,276)
Excess tax benefits related to stock-based compensation	1,700	2,831	14,850	10,365
Other	4	182	1,669	(3,432)

Net cash used in financing activities	(12,909)	(21,566)	(21,274)	(28,501)

Net change in cash and cash equivalents	76,442	3,996	33,682	19,594
Effect of exchange rate changes on cash and cash equivalents	(3,865)	2,930	4,282	4,468
Cash and cash equivalents, beginning of period	176,070	203,757	210,683	186,621

Cash and cash equivalents, end of period	\$ 248,647	\$ 210,683	\$ 248,647	\$ 210,683
=====				

Note: The above prior period amounts have been restated to reflect the effects of our adoption of FAS 123R using the modified retrospective application. Additionally, for the three months and year ended December 31, 2005, we reflected the effects of a reclassification of variable rate demand notes from 'cash and cash equivalents' to 'available-for-sale securities'.

Exhibit A

Henry Schein, Inc.
Sales Growth Rate Summary
2006

Q4 2006 over Q4 2005

	Consolidated Dental Medical International Technology				
	-----	-----	-----	-----	-----
Internal Sales Growth	2.3%	6.0%	-3.5%	3.3%	9.2%
Acquisitions, net of divestiture	7.0%	6.5%	9.6%	4.4%	6.2%

Local Currency Sales Growth	9.3%	12.5%	6.1%	7.7%	15.4%
Foreign Currency Exchange	2.3%	0.4%	-	8.2%	0.2%

Total Sales					

Growth	11.6%	12.9%	6.1%	15.9%	15.6%
Internal Sales Growth	2.3%	6.0%	-3.5%	3.3%	9.2%
Estimated Adjustment For Additional Week in Q405	5.0%	5.5%	5.0%	4.0%	8.5%
Adjusted Internal Sales Growth	7.3%	11.5%	1.5%	7.3%	17.7%

2006 over 2005

	Consolidated	Dental	Medical	International	Technology
Internal Sales Growth	5.2%	8.4%	0.6%	5.1%	8.6%
Acquisitions, net of divestiture	5.4%	3.5%	8.2%	5.6%	2.3%
Local Currency Sales Growth	10.6%	11.9%	8.8%	10.7%	10.9%
Foreign Currency Exchange	0.6%	0.8%	-	0.8%	0.4%
Total Sales Growth	11.2%	12.7%	8.8%	11.5%	11.3%
Internal Sales Growth	5.2%	8.4%	0.6%	5.1%	8.6%
Estimated Adjustment For Additional Week in 2005	1.5%	1.5%	1.5%	1.0%	2.0%
Adjusted Internal Sales Growth	6.7%	9.9%	2.1%	6.1%	10.6%

Use of Non-GAAP Measures:

The above information includes financial measures that are not calculated and presented in accordance with accounting principles generally accepted in the United States ("US GAAP"). The above table reconciles sales growth, excluding the effects of acquisitions, net of a divestiture and foreign currency exchange, to comparable amounts as adjusted to eliminate the effect of one additional week's sales activity from the comparable prior-year period.

Management eliminated the effect of such prior period's additional week's sales activity to assist in evaluating the underlying operational performance of the Company's business on a comparable basis. Management believes that this presentation is appropriate and facilitates such an evaluation by management, investors and analysts. This measure should be considered supplemental to, and not a substitute for or superior to, financial measures calculated in accordance with US GAAP.

CONTACT: Henry Schein, Inc.
Steven Paladino, 631-843-5500
Executive Vice President and Chief Financial Officer
steven.paladino@henryschein.com
or
Neal Goldner, 631-845-2820
Vice President, Investor Relations

neal.goldner@henryschein.com
or
Susan Vassallo, 631-843-5562
Director, Corporate Communications
susan.vassallo@henryschein.com

SOURCE: Henry Schein, Inc.